金沙检测线路js333-首页

  • Becoming a global leader in structural heart disease

  1. 1
  2. 2
  • Becoming a global leader in structural heart disease

  1. 1
  2. 2

Company Overview

---------

Founded in 2009, Venus Medtech is located in Hangzhou National High-Tech Industrial Development Zone (Binjiang) and is committed to the development and industrialization of transcatheter therapy products for structural heart disease. On December 10th, 2019, the company was listed on the main board of the Hong Kong Stock Exchange (SEHK) with stock code 02500.

The company's all series of “China Intelligently Manufactured " valves has been introduced to more than 30 countries and regions worldwide, including Asia, Europe, South America and North America, and has established a comprehensive heart valve line. By providing patients with a full range of TAVR solutions and accessory products, the company is committed to addressing the huge unmet demand of TPVR, TMVR and TTVR in China and around the world.

  • +

    +

    Employees

  • +

    Patent applications

  • > RMB

    million

    invested in R&D avg per year

  • +

    Real-world implantation cases

  • years

    The longest duration of clinical follow-up

  • +

    Centers nationwide

  • .43%

    Proportion of immediate safe surgery

As of Dec 2021

Global landscape


Russia

Thailand & Philippines

Malaysia
Indonesia

India

Pakistan

Jordan

Europe

UK

Ireland

Canada

USA

Brazil

Chile

Argentina

Baidu
sogou